SOPHIA presented their latest research results to a full auditorium at the International Congress on Obesity (ICO) in São Paulo, Brazil on 26 June.
Redefining how we think about obesity
"We had to redefine how we think about obesity, and this congress is really world leading," said SOPHIA coordinator Carel Le Roux from University College Dublin, "it is already talking about obesity as a disease."
Moderated by Miroslava Guajardo from Novo Nordisk and Elena Startseva from Boehringer Ingelheim, there was an inspiring dialogue about the results of SOPHIA, the predictors of obesity risk and response, obesity in those with T1D and the patient voice in SOPHIA.
Working together to improve obesity care
Ebaa Al Ozairi from Dasman Diabetes Institute and Werd Al-Najim from University College Dublin represented the entire SOPHIA consortium as they presented our research and discussed how we're working together to improve obesity care.
Thank you to the entire SOPHIA consortium, the symposium presenters, the International Congress on Obesity and the audience for participation. Stay tuned for more information on SOPHIA presentations and results happening around the world!
SOPHIA has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 875534. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and T1D Exchange, Breakthrough T1D (JDRF), and Obesity Action Coalition.